Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective

  • Verena Wieser
  • Alexander R. Moschen
  • Herbert TilgEmail author


Obesity and obesity-related disorders have dramatically increased globally in the last decades. These entities are commonly associated with a state of insulin resistance and the relationship between extensive lipid deposition and insulin resistance is widely accepted. The underlying mechanisms for insulin resistance, however, are still incompletely understood. Evidence from experimental research and human studies in the last years has suggested that innate immune pathways and inflammatory mechanisms also might play a role. Insulin resistance in case of obesity is commonly accompanied by low-grade systemic inflammation and adipose tissue inflammation. The expression of various pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6 is increased in adipose tissue and its expression linked to systemic inflammation and accompanying insulin resistance. Weight loss reduces this enhanced cytokine expression in the adipose tissue and thereby improves systemic inflammation. Whereas there is also substantial evidence that pro-inflammatory cytokines, certain members of the inflammasome and various transcription factors such as nuclear factor-κB play a major role in animal models of insulin resistance and type 2 diabetes, human studies neutralizing certain pro-inflammatory cytokines suggest so far that not all pro-inflammatory cytokines are of equal clinical importance. First clinical studies favor an important role for IL-1 family members and probably IL-6 but not for TNF-α in insulin-resistant states. Although we still have missing links in the understanding of insulin resistance, certain inflammatory pathways have also evolved in humans as central players.


Innate immunity Type 2 diabetes Adipocytokines Anti-cytokine therapies 



This work was supported by the Christian Doppler Society.


  1. Aguirre V, Uchida T, Yenush L et al (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275:9047–9054PubMedCrossRefGoogle Scholar
  2. Arkan MC, Hevener AL, Greten FR et al (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191–198PubMedCrossRefGoogle Scholar
  3. Barbuio R, Milanski M, Bertolo MB et al (2007) Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 194:539–550PubMedCrossRefGoogle Scholar
  4. Bernstein LE, Berry J, Kim S et al (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166:902–908PubMedCrossRefGoogle Scholar
  5. Cai D, Yuan M, Frantz DF et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183–190PubMedCrossRefGoogle Scholar
  6. Carstensen M, Herder C, Kivimaki M et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study. Diabetes 59:1222–1227PubMedCrossRefGoogle Scholar
  7. Clowes GH Jr, Martin H, Walji S et al (1978) Blood insulin responses to blood glucose levels in high output sepsis and septic shock. Am J Surg 135:577–583PubMedCrossRefGoogle Scholar
  8. da Silva BS, Bonfa E, de Moraes JC et al (2010) Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals 38:567–569PubMedCrossRefGoogle Scholar
  9. Dandona P, Weinstock R, Thusu K et al (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907–2910PubMedCrossRefGoogle Scholar
  10. Di Gregorio GB, Hensley L, Lu T et al (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182–E187PubMedCrossRefGoogle Scholar
  11. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732PubMedCrossRefGoogle Scholar
  12. Dominguez H, Storgaard H, Rask-Madsen C et al (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42:517–525PubMedCrossRefGoogle Scholar
  13. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107PubMedCrossRefGoogle Scholar
  14. Ebstein W (1876) Zur therapie des diabetes mellitus, insbesondere über die anwendeng der salicylauren natron bei demselben. Berliner Klinische Wochenschrift 13:337–340Google Scholar
  15. Ehses JA, Lacraz G, Giroix MH et al (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 106:13998–14003PubMedCrossRefGoogle Scholar
  16. Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489PubMedCrossRefGoogle Scholar
  17. Ferraz-Amaro I, Arce-Franco M, Muniz J et al (2011) Systemic blockade of TNF-α does not improve insulin resistance in humans. Horm Metab Res 43:801–808PubMedCrossRefGoogle Scholar
  18. Fu S, Watkins SM, Hotamisligil GS (2012) The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab 15:623–634PubMedCrossRefGoogle Scholar
  19. Glass CK, Olefsky JM (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15:635–645PubMedCrossRefGoogle Scholar
  20. Goldfine AB, Fonseca V, Jablonski KA et al (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346–357PubMedGoogle Scholar
  21. Goldfine AB, Buck S, Jablonski KA et al (2012) Targeting inflammation using SALsalate in patients with type 2 diabetes: effects on flow-mediated dilatation (TINSAL-FMD). Diabetes 61(Suppl 1):A303Google Scholar
  22. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83–86PubMedGoogle Scholar
  23. Hak AE, Stehouwer CD, Bots ML et al (1999) Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986–1991PubMedCrossRefGoogle Scholar
  24. He J, Usui I, Ishizuka K et al (2006) Interleukin-1 alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol 20:114–124PubMedCrossRefGoogle Scholar
  25. Hingorani AD, Casas JP (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379:1214–1224PubMedCrossRefGoogle Scholar
  26. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMedCrossRefGoogle Scholar
  27. Hotamisligil GS, Peraldi P, Budavari A et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMedCrossRefGoogle Scholar
  28. Hundal RS, Petersen KF, Mayerson AB et al (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321–1326PubMedGoogle Scholar
  29. Kamari Y, Shaish A, Vax E et al (2011) Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 55:1086–1094PubMedCrossRefGoogle Scholar
  30. Kanda H, Tateya S, Tamori Y et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494–1505PubMedCrossRefGoogle Scholar
  31. Kern PA, Saghizadeh M, Ong JM et al (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111–2119PubMedCrossRefGoogle Scholar
  32. Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–3427PubMedCrossRefGoogle Scholar
  33. Kopp HP, Kopp CW, Festa A et al (2003) Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23:1042–1047PubMedCrossRefGoogle Scholar
  34. Koutroubakis IE, Oustamanolakis P, Malliaraki N et al (2009) Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 21:283–288PubMedCrossRefGoogle Scholar
  35. Lagathu C, Yvan-Charvet L, Bastard JP et al (2006) Long-term treatment with interleukin-1 beta induces insulin resistance in murine and human adipocytes. Diabetologia 49:2162–2173PubMedCrossRefGoogle Scholar
  36. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526PubMedCrossRefGoogle Scholar
  37. Larsen CM, Faulenbach M, Vaag A et al (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668PubMedCrossRefGoogle Scholar
  38. Li Z, Yang S, Lin H et al (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343–350PubMedCrossRefGoogle Scholar
  39. Mehta NN, McGillicuddy FC, Anderson PD et al (2010) Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 59:172–181PubMedCrossRefGoogle Scholar
  40. Meier CA, Bobbioni E, Gabay C et al (2002) IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87:1184–1188PubMedCrossRefGoogle Scholar
  41. Miura K, Kodama Y, Inokuchi S et al (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139(323–334):e7PubMedGoogle Scholar
  42. Moschen AR, Molnar C, Geiger S et al (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259–1264PubMedCrossRefGoogle Scholar
  43. Moschen AR, Molnar C, Enrich B et al (2011) Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med 17:840–845PubMedCrossRefGoogle Scholar
  44. Nold MF, Nold-Petry CA, Zepp JA et al (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014–1022PubMedCrossRefGoogle Scholar
  45. Ofei F, Hurel S, Newkirk J et al (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885PubMedCrossRefGoogle Scholar
  46. Ogata A, Morishima A, Hirano T et al (2011) Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70:1164–1165PubMedCrossRefGoogle Scholar
  47. Owyang AM, Maedler K, Gross L et al (2010) XOMA 052, an anti-IL-1beta monoclonal antibody, improves glucose control and beta-cell function in the diet-induced obesity mouse model. Endocrinology 151:2515–2527PubMedCrossRefGoogle Scholar
  48. Paquot N, Castillo MJ, Lefebvre PJ et al (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316–1319PubMedCrossRefGoogle Scholar
  49. Pihlajamaki J, Kuulasmaa T, Kaminska D et al (2012) Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol 56:663–670PubMedCrossRefGoogle Scholar
  50. Pradhan AD, Cook NR, Manson JE et al (2009) A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 32:3–8PubMedCrossRefGoogle Scholar
  51. Raymond RM, Harkema JM, Emerson TE Jr (1981) In vivo skeletal muscle insulin resistance during E. coli endotoxin shock in the dog. Circ Shock 8:425–433PubMedGoogle Scholar
  52. Ridker PM, Thuren T, Zalewski A et al (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597–605PubMedCrossRefGoogle Scholar
  53. Rosenvinge A, Krogh-Madsen R, Baslund B et al (2007) Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 36:91–96PubMedCrossRefGoogle Scholar
  54. Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148:852–871PubMedCrossRefGoogle Scholar
  55. Schultz O, Oberhauser F, Saech J et al (2010) Effects of inhibition of interleukin-6 signaling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 5:e14328PubMedCrossRefGoogle Scholar
  56. Stienstra R, Tack CJ, Kanneganti TD et al (2012) The inflammasome puts obesity in the danger zone. Cell Metab 15:10–18PubMedCrossRefGoogle Scholar
  57. Svenson KL, Lundqvist G, Wide L et al (1987) Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 36:940–943PubMedCrossRefGoogle Scholar
  58. Uysal KT, Wiesbrock SM, Marino MW et al (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610–614PubMedCrossRefGoogle Scholar
  59. Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79PubMedCrossRefGoogle Scholar
  60. Wascher TC, Lindeman JH, Sourij H et al (2011) Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in “healthy” men with metabolic syndrome. Mol Med 17:189–193PubMedCrossRefGoogle Scholar
  61. Weisberg SP, McCann D, Desai M et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808PubMedGoogle Scholar
  62. Weisberg SP, Hunter D, Huber R et al (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115–124PubMedCrossRefGoogle Scholar
  63. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77–80PubMedCrossRefGoogle Scholar
  64. Yuan M, Konstantopoulos N, Lee J et al (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677PubMedCrossRefGoogle Scholar
  65. Yudkin JS, Stehouwer CD, Emeis JJ et al (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMedCrossRefGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2013

Authors and Affiliations

  • Verena Wieser
    • 1
  • Alexander R. Moschen
    • 1
  • Herbert Tilg
    • 1
    Email author
  1. 1.Department of Medicine I, GastroenterologyEndocrinology and Metabolism and Christian Doppler Research Laboratory for Gut Inflammation, Medical University InnsbruckInnsbruckAustria

Personalised recommendations